Abstract:Objective To explore the serum level of complement 1q (C1q) in systemic lupus erythematosus patients and to analyze its significance in diagnosis and prognosis of systemic lupus erythematosus with lupus flare and lupus nephritis (LN). Methods According to the clinical data, 150 cases of subjects were divided into four groups. There were 60 cases in SLE group, 30 cases in other rheumatic disease group, 30 cases in other kidney disease group and 30 cases in normal control group. The SLE group contained 33 cases of LN patients and 27 cases of non-LN patients. The serum level of C1q was measured by immune transmission turbidimetry. The correlations between the serum level of C1q and other disease activity parameters such as SLEDAI scores, C3 and C4 levels were analyzed. Results The serum level of C1q in the SLE group was significantly lower than that of the other rheumatic disease group, the other kidney disease group and the normal control group (F = 41.428, P = 0.000). The LN patients showed a significantly lower level of serum C1q than the non-LN patients (t = -4.262, P = 0.000). The SLE patients in active stage showed a significantly lower level of serum C1q than the stable patients (t = -5.159, P = 0.000). The sensitivity and specificity of C1q to diagnose LN in the SLE group were 66.7% and 59.3% respectively. The area under ROC curve was 0.717. Correlation analysis showed that the serum level of C1q was positively correlated with C3 and C4 concentrations but negatively correlated with the SLEDAI scores (r = 0.593, 0.448 and -0.589 respectively, and P = 0.000). Conclusions C1q may not only contribute to the diagnosis of SLE and LN, but also reflect the disease activity and treatment effect.